Mecwins has been granted with more than 1.4M€ to develop ultrasensitive optoplasmonic immunoassays for the early detection of breast cancer under the Líneas Estratégicas Program

Mecwins, in collaboration with the Bionanomechanics Lab from IMN-CSIC (Instituto de Micro y Nanotecnología de Madrid), with the CNIO (Spanish National Cancer Research Center), and with the Foundation for Biomedical Research of the 12 de Octubre University Hospital will carry out a project to develop ultrasensitive optoplasmonic immunoassays for the early detection of breast cancer.

The project: “Oncodeeplasm: Platform of ultrasensitive optoplasmonic immunoassays for the early detection of breast cancer based on protein biomarkers of the blood’s deep proteome region” will get more than 1.4M€.